prostaglandin-d2 and Leg-Ulcer

Macrophages undergo a transition from pro-inflammatory to healing-associated phenotypes that is critical for efficient wound healing. However, the regulation of this transition during normal and impaired healing remains to be elucidated. In our studies, the switch in macrophage phenotypes during skin wound healing was associated with up-regulation of the peroxisome proliferator-activated receptor (PPAR)γ and its downstream targets, along with increased mitochondrial content. In the setting of diabetes, up-regulation of PPARγ activity was impaired by sustained expression of IL-1β in both mouse and human wounds. In addition, experiments with myeloid-specific PPARγ knockout mice indicated that loss of PPARγ in macrophages is sufficient to prolong wound inflammation and delay healing. Furthermore, PPARγ agonists promoted a healing-associated macrophage phenotype both in vitro and in vivo, even in the diabetic wound environment. Importantly, topical administration of PPARγ agonists improved healing in diabetic mice, suggesting an appealing strategy for down-regulating inflammation and improving the healing of chronic wounds.

Topics: Administration, Cutaneous; Animals; Cells, Cultured; Diabetes Mellitus, Type 1; Disease Models, Animal; Female; Humans; Interleukin-1beta; Leg Ulcer; Macrophages; Male; Mice, Inbred C57BL; Mice, Knockout; Phenotype; PPAR gamma; Prostaglandin D2; Receptors, Interleukin-1 Type I; Rosiglitazone; Skin; Thiazolidinediones; Time Factors; Wound Healing